CIBC Asset Management
TGTX icon

CIBC Asset Management’s TG Therapeutics TGTX Stock Holding History

CIBC Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Buy
+4,786
New +$196K ﹤0.01% 1138

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

CIBC Asset Management's TGTX Position: Q2 2026 in Review

CIBC Asset Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 4,786 shares worth $263K. The stake represents ﹤0.01% of the portfolio and ranks #1138 among its holdings.

427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • CIBC Asset Management held 4,786 shares of TG Therapeutics worth $263K as of Q2 2026.
  • TG Therapeutics was a new CIBC Asset Management position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1138 holding.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.